View all trials
Are you a member? Sign in above to view additional information
  • Study title
    A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
  • Protocol ID
    EZH102
  • Disease
    Disease Type Disease Subtype
    Solid tumours All
  • Eligibility criteria
  • Study Status
    Open
  • Location(s)
    Children's Hospital at Westmead
    • Centre Study Status:
      Open
    • Notes:
    Lady Cilento Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
    Royal Children's Hospital Melbourne
    • Centre Study Status:
      Open
    • Notes:
    Sydney Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
  • Phase
    Phase 1
  • Study type
    Treatment
  • Diagnosis stage
    Relapse/refractory
  • Study open date
    27/05/2016
  • Study close date
    N/A
  • Study chair
    Peter Ho, Chief Medical Officer
  • Sponsor
    Epizyme
Back to search results